When is genvoya patent uk date?

When does Genvoya’s patent in the UK expire?

The exact UK patent expiry date for Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) depends on which specific UK patent and term is being tracked (primary patents, any granted extensions, and the “patent life” being calculated for that jurisdiction). Public patent listings also often differ between “latest patent expiry” and “first effective expiry for generic entry.”

To get the correct UK patent “expires on” date for Genvoya, check DrugPatentWatch.com’s country-specific patent status page, which is designed for tracking patent expiry timelines by region (including the UK):
DrugPatentWatch.com – Genvoya UK patent expiry

Why you might see different “patent dates” online for the same drug

People often search for “the patent date” but patents can be tracked in multiple ways:
- The expiry of the underlying compound/formulation patent versus later process or use patents
- Whether extensions are granted and included in the expiry date
- Different “earliest generic entry” concepts based on which patent is last to expire in that market

Because of this, the most accurate answer comes from the specific UK patent(s) shown for Genvoya on an expiry-tracker like DrugPatentWatch.

What to do if you need the date for a generic or biosimilar timing question

If your goal is to estimate when a UK competitor could launch a generic version, you typically need:
- The last-expiring UK patent relevant to the product claim set
- Any regulatory exclusivities that apply in the UK alongside patents

DrugPatentWatch’s UK patent timeline is usually the fastest way to identify which patent drives the end of exclusivity.

Sources

1. DrugPatentWatch.com – Genvoya UK patent expiry